- Home
- URGN vs NQP Comparison
URGN vs NQP Comparison
Compare URGN & NQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NQP
- Stock Information
- Founded
- URGN 2004
- NQP 1990
- Country
- URGN United States
- NQP United States
- Employees
- URGN N/A
- NQP N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NQP Trusts Except Educational Religious and Charitable
- Sector
- URGN Health Care
- NQP Finance
- Exchange
- URGN Nasdaq
- NQP Nasdaq
- Market Cap
- URGN 465.9M
- NQP 438.1M
- IPO Year
- URGN 2017
- NQP N/A
- Fundamental
- Price
- URGN $10.27
- NQP $11.30
- Analyst Decision
- URGN Strong Buy
- NQP
- Analyst Count
- URGN 5
- NQP 0
- Target Price
- URGN $44.50
- NQP N/A
- AVG Volume (30 Days)
- URGN 487.3K
- NQP 58.4K
- Earning Date
- URGN 03-13-2025
- NQP 01-01-0001
- Dividend Yield
- URGN N/A
- NQP 3.21%
- EPS Growth
- URGN N/A
- NQP N/A
- EPS
- URGN N/A
- NQP N/A
- Revenue
- URGN $89,363,000.00
- NQP N/A
- Revenue This Year
- URGN $13.39
- NQP N/A
- Revenue Next Year
- URGN $45.06
- NQP N/A
- P/E Ratio
- URGN N/A
- NQP N/A
- Revenue Growth
- URGN 15.64
- NQP N/A
- 52 Week Low
- URGN $9.78
- NQP $9.65
- 52 Week High
- URGN $20.70
- NQP $11.89
- Technical
- Relative Strength Index (RSI)
- URGN 39.53
- NQP 43.24
- Support Level
- URGN $10.12
- NQP $11.15
- Resistance Level
- URGN $10.96
- NQP $11.43
- Average True Range (ATR)
- URGN 0.57
- NQP 0.09
- MACD
- URGN -0.01
- NQP 0.02
- Stochastic Oscillator
- URGN 24.75
- NQP 64.47
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NQP Nuveen Pennsylvania Quality Municipal Income Fund
Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.